Retatrutide, a weekly injection from Eli Lilly, cut pain and weight, but it also caused stomach trouble.
A weekly shot for sore knees
On November 8, the New England Journal of Medicine published the results of a pair of large trials of a drug called retatrutide. It is an experimental weekly shot from Eli Lilly. More than 1,000 adults took part. All were overweight or obese, and all had sore knees from osteoarthritis, a condition in which the cushion inside the joint wears down. People on the drug felt less pain and lost a lot of weight. You cannot buy it anywhere yet.
Three targets in one shot
Cells have docking spots where hormones attach and pass on their messages. Drugs already on sale, such as Wegovy and Mounjaro, work on one or two of these spots. Retatrutide works on three at once.
Dr. Thomas Schnitzer of Northwestern University led the research. He says a major factor is simple: lighter people put less load on their knees, so they hurt less. Citing earlier research, the team adds that each pound lost takes about 4 pounds of load off the knee. Schnitzer says these drugs are also believed to calm inflammation, but how is not entirely known. The results below show what happened, not why.
“I believe the pain relief is real, but I want proof that the joints themselves hold up.”
How much the pain fell
In each trial, some people got a placebo, a dummy shot with no drug in it. People rated their knee pain from 0 to 10, where 10 is the worst. In the first trial, which ran 68 weeks, the average pain score fell by 3.96 points on the lower dose and 3.74 on the higher one. The two doses worked about the same. On placebo, it fell by 2.12 points. Across both trials, about two-thirds of people on the drug saw their pain fall by half or more. Even on placebo, 37.8% did, a little over a third. So a dummy shot can bring relief too.
Weight loss was large too. In the second trial, which ran 80 weeks, average weight loss ranged from 17.5% of body weight on the lowest dose to 24.8% on the highest. On the top dose, that is close to a quarter of a person's weight. On placebo, the loss was 4.3%. What did the shot cost the people who took it?
What the shot costs the body
Most side effects hit the stomach: nausea, diarrhea and constipation. They came mainly while doctors raised the dose in steps every four weeks. In the first trial, nausea struck 43.2% of people on the top dose, against 10.7% on placebo.
Muscle loss is a known side effect of these drugs: some of the weight that comes off is muscle. Schnitzer says keeping muscle matters for people with sore knees, because muscle helps hold the knee steady.
Serious health problems were also more common: 10.8% of people on the top dose had one, against 2.0% on placebo. The count includes problems the drug may not have caused. And 18.2% of the top-dose group stopped treatment because of side effects, against 4.0% on placebo. Lilly says some of those who stopped felt they were losing too much weight.
What the trials could not show
Anyone who needed a knee replacement was left out. Nobody knows if the shot helps people of normal weight, because none took part. The researchers add that the trials were too short to judge long-term safety or how long the benefits last. Schnitzer's biggest unknown is mine too: does the drug slow the disease enough to cut the need for a joint replacement? I keep thinking that a pain score is a feeling, and a feeling is not the same as a joint. Less pain does not prove the cushion stopped wearing down. Fewer replacements later on would be the proof I want. These trials were not built to tell.
Eli Lilly paid for both trials and helped design them. The company now expects to file for approval in the first quarter of 2027. Until then, Schnitzer says, the first step should be diet, exercise and lifestyle changes. They cost less and are not linked to the stomach trouble or muscle loss. He says retatrutide would be a good option for people who cannot lose weight and still hurt, if U.S. regulators approve it.
Nov 9, 2026
